|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Epidemiology/Health Services/Psychosocial Research |
Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes
1 Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
2 Institute of Health Economics, Edmonton, Alberta, Canada
3 Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
OBJECTIVE—The aim of this study was to examine the relationship between use of metformin and sulfonylurea and mortality in new users of these agents.
RESEARCH DESIGN AND METHODS—Saskatchewan Health databases were used to examine population-based mortality rates for new users of oral antidiabetic agents. Individuals with prescriptions for sulfonylurea or metformin in 1991–1996 and no use in the year prior were identified as new users. Prescription records were prospectively followed for 1–9 years; subjects with any insulin use were excluded. Causes of death were identified based on ICD-9 codes in an electronic vital statistics database. Multivariate logistic regression and survival analyses were used to assess the differences in mortality between drug cohorts, after adjusting for potential confounding variables.
RESULTS—The total study sample comprised 12,272 new users of oral antidiabetic agents; the average length of follow-up was 5.1 (SD 2.2) years. In subjects with at least 1 year of drug exposure and no insulin use, mortality rates were 750/3,033 (24.7%) for those receiving sulfonylurea monotherapy, 159/1,150 (13.8%) for those receiving metformin monotherapy, and 635/4,683 (13.6%) for those receiving combination therapy over an average 5.1 (SD 2.2) years of follow-up. The adjusted odds ratio (OR) for all-cause mortality for metformin monotherapy was 0.60 (95% CI 0.49–0.74) compared with sulfonylurea monotherapy. Sulfonylurea plus metformin combination therapy was also associated with reduced all-cause mortality (OR 0.66, 95% CI 0.58–0.75). Reduced cardiovascular-related mortality rates were also observed in metformin users compared with sulfonylurea monotherapy users.
CONCLUSIONS—Metformin therapy, alone or in combination with sulfonylurea, was associated with reduced all-cause and cardiovascular mortality compared with sulfonylurea monotherapy among new users of these agents.
Abbreviations: CDS, Chronic Disease Score • OR, odds ratio • RR, relative risk • UKPDS, U.K. Prospective Diabetes Study
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. D. Rao, N. Kuhadiya, K. Reynolds, and V. A. Fonseca Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies Diabetes Care, August 1, 2008; 31(8): 1672 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Standl and O. Schnell Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted? Diabetes Care, February 1, 2008; 31(Supplement_2): S136 - S139. [Full Text] [PDF]
|
|
|
|
 |
|
 A A Tahrani, G I Varughese, J H Scarpello, and F W F Hanna Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ, September 8, 2007; 335(7618): 508 - 512. [Full Text] [PDF]
|
|
|
|
|
|
D. T Eurich, F. A McAlister, D. F Blackburn, S. R Majumdar, R. T Tsuyuki, J. Varney, and J. A Johnson Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review BMJ, September 8, 2007; 335(7618): 497 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Kahler, M. Rajan, G. G. Rhoads, M. M. Safford, K. Demissie, S.-E. Lu, and L. M. Pogach Impact of Oral Antihyperglycemic Therapy on All-Cause Mortality Among Patients With Diabetes in the Veterans Health Administration Diabetes Care, July 1, 2007; 30(7): 1689 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jeerakathil, J. A. Johnson, S. H. Simpson, and S. R. Majumdar Short-Term Risk for Stroke Is Doubled in Persons With Newly Treated Type 2 Diabetes Compared With Persons Without Diabetes: A Population-Based Cohort Study Stroke, June 1, 2007; 38(6): 1739 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F A McAlister, S R Majumdar, D T Eurich, and J A Johnson The effect of specialist care within the first year on subsequent outcomes in 24 232 adults with new-onset diabetes mellitus: population-based cohort study Qual. Saf. Health Care, February 1, 2007; 16(1): 6 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Ong, L. M. Molyneaux, M. I. Constantino, S. M. Twigg, and D. K. Yue Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care, November 1, 2006; 29(11): 2361 - 2364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jadhav, W. Ferrell, I. A. Greer, J. R. Petrie, S. M. Cobbe, and N. Sattar Effects of Metformin on Microvascular Function and Exercise Tolerance in Women With Angina and Normal Coronary Arteries: A Randomized, Double-Blind, Placebo-Controlled Study J. Am. Coll. Cardiol., September 5, 2006; 48(5): 956 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Maddigan, D. H. Feeny, S. R. Majumdar, K. B. Farris, and J. A. Johnson Understanding the Determinants of Health for People With Type 2 Diabetes Am J Public Health, September 1, 2006; 96(9): 1649 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Bowker, S. R. Majumdar, P. Veugelers, and J. A. Johnson Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin Diabetes Care, February 1, 2006; 29(2): 254 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Simpson, S. R. Majumdar, R. T. Tsuyuki, D. T. Eurich, and J. A. Johnson Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study Can. Med. Assoc. J., January 17, 2006; 174(2): 169 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Eurich, S. R. Majumdar, F. A. McAlister, R. T. Tsuyuki, and J. A. Johnson Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure Diabetes Care, October 1, 2005; 28(10): 2345 - 2351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. McDonald, S. R. Majumdar, J. L. Mahon, and J. A. Johnson The Effectiveness of {beta}-Blockers After Myocardial Infarction in Patients With Type 2 Diabetes Diabetes Care, September 1, 2005; 28(9): 2113 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Brown, S. R. Majumdar, S. C. Newman, and J. A. Johnson History of Depression Increases Risk of Type 2 Diabetes in Younger Adults Diabetes Care, May 1, 2005; 28(5): 1063 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Brown, J. A. Johnson, S. R. Majumdar, R. T. Tsuyuki, and F. A. McAlister Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis Can. Med. Assoc. J., November 9, 2004; 171(10): 1189 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dandona, A. Aljada, H. Ghanim, P. Mohanty, C. Tripathy, D. Hofmeyer, and A. Chaudhuri Increased Plasma Concentration of Macrophage Migration Inhibitory Factor (MIF) and MIF mRNA in Mononuclear Cells in the Obese and the Suppressive Action of Metformin J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5043 - 5047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Caballero, A. Delgado, C. A. Aguilar-Salinas, A. N. Herrera, J. L. Castillo, T. Cabrera, F. J. Gomez-Perez, and J. A. Rull The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3943 - 3948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Eurich, S. R. Majumdar, R. T. Tsuyuki, and J. A. Johnson Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1330 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J Meier, B Gallwitz, W E Schmidt, A Mugge, and M A Nauck Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart, January 1, 2004; 90(1): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Lavanchy, G. Christe, F. Cand, N. Wiernsperger, and J. Verdetti Effects of chronic treatment with glibenclamide and/or metformin on the resistance to ischaemia of isolated hearts from Zucker Diabetic Fatty rats (ZDF/GMI-fa/fa) The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 375 - 380. [Abstract] [PDF]
|
|
|
|
 |
|
 D. K. Plante and J. L. Nadler Diabetes and Vascular Disease Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 295 - 310. [Abstract] [PDF]
|
|
|
|
|
|
A. J. Garber, D. S. Donovan Jr., P. Dandona, S. Bruce, and J.-S. Park Efficacy of Glyburide/Metformin Tablets Compared with Initial Monotherapy in Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3598 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Abraira and W. Duckworth The Need for Glycemic Trials in Type 2 Diabetes Clin. Diabetes, July 1, 2003; 21(3): 107 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dandona, A. Aljada, A. Chaudhuri, and A. Bandyopadhyay The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2422 - 2429. [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932. [Full Text] [PDF]
|
|
|
|
|
|
A. Sasali and J. L. Leahy Is Metformin Cardioprotective? Diabetes Care, January 1, 2003; 26(1): 243 - 244. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |